Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.80 (+1.14%) Hang Seng
18,079.61 -150.59 (-0.83%) FTSE 100
8,282.04 +50.99 (+0.62%) Bitcoin USD
68,755.88 +669.20 (+0.98%) CMC Crypto 200
1,442.76 +14.19 (+0.99%)
Teva Pharmaceutical Industries Limited (TEVA)
Pre-market:
| Previous close | 16.45 |
| Open | 16.52 |
| Bid | 16.86 x 3200 |
| Ask | 16.89 x 4000 |
| Day's range | 16.49 - 16.92 |
| 52-week range | 7.12 - 17.13 |
| Volume | |
| Avg. volume | 9,806,888 |
| Market cap | 19.142B |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.42 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 27 Nov 2017 |
| 1y target est | 17.88 |
Business WireTeva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
TEL AVIV, Israel & PARSIPPANY, N.J., May 29, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO XR as a one pill, once-daily treatment option, now with four new tablet strengths (30, 36, 42, 48 mg) indicated in adults for TD and HD chorea.
Business WireTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 21, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult pla
GuruFocus.comInsider Sale: Chief Accounting Officer Amir Weiss Sells 28,135 Shares of Teva Pharmaceutical ...
On May 16, 2024, Amir Weiss, the Chief Accounting Officer of Teva Pharmaceutical Industries Ltd (NYSE:TEVA), executed a sale of 28,135 shares of the company.
